These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 32071334)

  • 1. Targeting Oncogenic Super Enhancers in MYC-Dependent AML Using a Small Molecule Activator of NR4A Nuclear Receptors.
    Call SG; Duren RP; Panigrahi AK; Nguyen L; Freire PR; Grimm SL; Coarfa C; Conneely OM
    Sci Rep; 2020 Feb; 10(1):2851. PubMed ID: 32071334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug targeting of NR4A nuclear receptors for treatment of acute myeloid leukemia.
    Boudreaux SP; Duren RP; Call SG; Nguyen L; Freire PR; Narayanan P; Redell MS; Conneely OM
    Leukemia; 2019 Jan; 33(1):52-63. PubMed ID: 29884904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genome Wide Mapping of NR4A Binding Reveals Cooperativity with ETS Factors to Promote Epigenetic Activation of Distal Enhancers in Acute Myeloid Leukemia Cells.
    Duren RP; Boudreaux SP; Conneely OM
    PLoS One; 2016; 11(3):e0150450. PubMed ID: 26938745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disruption of BRD4 at H3K27Ac-enriched enhancer region correlates with decreased c-Myc expression in Merkel cell carcinoma.
    Sengupta D; Kannan A; Kern M; Moreno MA; Vural E; Stack B; Suen JY; Tackett AJ; Gao L
    Epigenetics; 2015; 10(6):460-6. PubMed ID: 25941994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aberrant Super-Enhancer Landscape in Human Hepatocellular Carcinoma.
    Tsang FH; Law CT; Tang TC; Cheng CL; Chin DW; Tam WV; Wei L; Wong CC; Ng IO; Wong CM
    Hepatology; 2019 Jun; 69(6):2502-2517. PubMed ID: 30723918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mediator kinase inhibition further activates super-enhancer-associated genes in AML.
    Pelish HE; Liau BB; Nitulescu II; Tangpeerachaikul A; Poss ZC; Da Silva DH; Caruso BT; Arefolov A; Fadeyi O; Christie AL; Du K; Banka D; Schneider EV; Jestel A; Zou G; Si C; Ebmeier CC; Bronson RT; Krivtsov AV; Myers AG; Kohl NE; Kung AL; Armstrong SA; Lemieux ME; Taatjes DJ; Shair MD
    Nature; 2015 Oct; 526(7572):273-276. PubMed ID: 26416749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transcriptional plasticity promotes primary and acquired resistance to BET inhibition.
    Rathert P; Roth M; Neumann T; Muerdter F; Roe JS; Muhar M; Deswal S; Cerny-Reiterer S; Peter B; Jude J; Hoffmann T; Boryń ŁM; Axelsson E; Schweifer N; Tontsch-Grunt U; Dow LE; Gianni D; Pearson M; Valent P; Stark A; Kraut N; Vakoc CR; Zuber J
    Nature; 2015 Sep; 525(7570):543-547. PubMed ID: 26367798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia.
    Zuber J; Shi J; Wang E; Rappaport AR; Herrmann H; Sison EA; Magoon D; Qi J; Blatt K; Wunderlich M; Taylor MJ; Johns C; Chicas A; Mulloy JC; Kogan SC; Brown P; Valent P; Bradner JE; Lowe SW; Vakoc CR
    Nature; 2011 Aug; 478(7370):524-8. PubMed ID: 21814200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Small Molecules Co-targeting CKIα and the Transcriptional Kinases CDK7/9 Control AML in Preclinical Models.
    Minzel W; Venkatachalam A; Fink A; Hung E; Brachya G; Burstain I; Shaham M; Rivlin A; Omer I; Zinger A; Elias S; Winter E; Erdman PE; Sullivan RW; Fung L; Mercurio F; Li D; Vacca J; Kaushansky N; Shlush L; Oren M; Levine R; Pikarsky E; Snir-Alkalay I; Ben-Neriah Y
    Cell; 2018 Sep; 175(1):171-185.e25. PubMed ID: 30146162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plk1 Inhibition Enhances the Efficacy of BET Epigenetic Reader Blockade in Castration-Resistant Prostate Cancer.
    Mao F; Li J; Luo Q; Wang R; Kong Y; Carlock C; Liu Z; Elzey BD; Liu X
    Mol Cancer Ther; 2018 Jul; 17(7):1554-1565. PubMed ID: 29716963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR-766-5p Targets Super-Enhancers by Downregulating CBP and BRD4.
    Gen Y; Muramatsu T; Inoue J; Inazawa J
    Cancer Res; 2021 Oct; 81(20):5190-5201. PubMed ID: 34353856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual Targeting of Bromodomain and Extraterminal Domain Proteins, and WNT or MAPK Signaling, Inhibits c-MYC Expression and Proliferation of Colorectal Cancer Cells.
    Tögel L; Nightingale R; Chueh AC; Jayachandran A; Tran H; Phesse T; Wu R; Sieber OM; Arango D; Dhillon AS; Dawson MA; Diez-Dacal B; Gahman TC; Filippakopoulos P; Shiau AK; Mariadason JM
    Mol Cancer Ther; 2016 Jun; 15(6):1217-26. PubMed ID: 26983878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of SWI/SNF in acute leukemia maintenance and enhancer-mediated Myc regulation.
    Shi J; Whyte WA; Zepeda-Mendoza CJ; Milazzo JP; Shen C; Roe JS; Minder JL; Mercan F; Wang E; Eckersley-Maslin MA; Campbell AE; Kawaoka S; Shareef S; Zhu Z; Kendall J; Muhar M; Haslinger C; Yu M; Roeder RG; Wigler MH; Blobel GA; Zuber J; Spector DL; Young RA; Vakoc CR
    Genes Dev; 2013 Dec; 27(24):2648-62. PubMed ID: 24285714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the Epigenetic Reader ENL Inhibits Super-Enhancer-Driven Oncogenic Transcription and Synergizes with BET Inhibition to Suppress Tumor Progression.
    Chen Y; Ying Y; Ma W; Ma H; Shi L; Gao X; Jia M; Li M; Song X; Kong W; Chen W; Zheng X; Muluh TA; Wang X; Wang M; Shu XS
    Cancer Res; 2024 Apr; 84(8):1237-1251. PubMed ID: 38241700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of MLL-fusion/MYC⊣miR-26⊣TET1 signaling circuit in MLL-rearranged leukemia.
    Huang H; Jiang X; Wang J; Li Y; Song CX; Chen P; Li S; Gurbuxani S; Arnovitz S; Wang Y; Weng H; Neilly MB; He C; Li Z; Chen J
    Cancer Lett; 2016 Mar; 372(2):157-65. PubMed ID: 26791235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies.
    Rhyasen GW; Hattersley MM; Yao Y; Dulak A; Wang W; Petteruti P; Dale IL; Boiko S; Cheung T; Zhang J; Wen S; Castriotta L; Lawson D; Collins M; Bao L; Ahdesmaki MJ; Walker G; O'Connor G; Yeh TC; Rabow AA; Dry JR; Reimer C; Lyne P; Mills GB; Fawell SE; Waring MJ; Zinda M; Clark E; Chen H
    Mol Cancer Ther; 2016 Nov; 15(11):2563-2574. PubMed ID: 27573426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MYC-driven epigenetic reprogramming favors the onset of tumorigenesis by inducing a stem cell-like state.
    Poli V; Fagnocchi L; Fasciani A; Cherubini A; Mazzoleni S; Ferrillo S; Miluzio A; Gaudioso G; Vaira V; Turdo A; Gaggianesi M; Chinnici A; Lipari E; Bicciato S; Bosari S; Todaro M; Zippo A
    Nat Commun; 2018 Mar; 9(1):1024. PubMed ID: 29523784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRD4 Inhibitor GNE-987 Exerts Anticancer Effects by Targeting Super-Enhancer-Related Gene LYL1 in Acute Myeloid Leukemia.
    Sang X; Zhang Y; Fang F; Gao L; Tao Y; Li X; Zhang Z; Wang J; Tian Y; Li Z; Yao D; Wu Y; Chu X; Zhang K; Ma L; Lu L; Chen Y; Yu J; Zhuo R; Wu S; Zhang Z; Pan J; Hu S
    J Immunol Res; 2022; 2022():7912484. PubMed ID: 35958877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genome-wide profiling reveals transcriptional repression of MYC as a core component of NR4A tumor suppression in acute myeloid leukemia.
    Boudreaux SP; Ramirez-Herrick AM; Duren RP; Conneely OM
    Oncogenesis; 2012 Jul; 1(7):e19. PubMed ID: 23552735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recurrent mutations, including NPM1c, activate a BRD4-dependent core transcriptional program in acute myeloid leukemia.
    Dawson MA; Gudgin EJ; Horton SJ; Giotopoulos G; Meduri E; Robson S; Cannizzaro E; Osaki H; Wiese M; Putwain S; Fong CY; Grove C; Craig J; Dittmann A; Lugo D; Jeffrey P; Drewes G; Lee K; Bullinger L; Prinjha RK; Kouzarides T; Vassiliou GS; Huntly BJ
    Leukemia; 2014 Feb; 28(2):311-20. PubMed ID: 24220271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.